BARDA funds two first-in-human studies for Regeneron’s COVID-19 antibody cocktail
One of BARDA’s first private sector partners in the COVID-19 response, Regeneron, has begun the first clinical trials of REGN-COV2, its therapeutic two-antibody “cocktail” for COVID-19 patients. This treatment, developed with BARDA support, has the potential to be one of the first therapeutics specifically designed to inhibit SARS-COV-2, the virus that causes COVID-19.
The therapeutic contains two neutralizing monoclonal antibodies. Neutralizing monoclonal antibodies were initially identified from Regeneron’s proprietary genetically-humanized VelocImmune® mice and from COVID-19 convalescent patient blood and then expanded and manufactured in large quantities. The investigational antibody cocktail may help COVID-19 patients recover from the disease more quickly, while simultaneously giving the patients more time to develop their own antibodies to fight the infection. Regeneron is also planning to explore REGN-COV2’s potential for preventing SARS-CoV-2 infection in people who have not yet been infected by the virus.
In order to address any potential mutation, a cocktail of two monoclonal antibodies that neutralize SARS-CoV-2 and bind to non-overlapping regions of the virus’s spike protein was selected to reduce the chance that the virus would be able to ‘escape’ treatment and evolve into a treatment-resistant strain. With a multi-antibody approach, the virus would need multiple simultaneously mutations in multiple genetic locations in order to evade neutralization.
These initial Phase 1/Phase 2 clinical trials will provide the first data on the safety and efficacy of the treatment in hospitalized and non-hospitalized patient volunteers with symptomatic COVID-19. Currently, there are no FDA-approved COVID-19 treatments.
This award is one component of BARDA’s rapidly expanding COVID-19 medical countermeasure portfolio; visit BARDA’s COVID-19 Portfolio to learn more.
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, Regeneron’s unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in the company’s laboratories. Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.